ECSP14013212A - Inhibidores de la tirosina-quinasa de bruton - Google Patents

Inhibidores de la tirosina-quinasa de bruton

Info

Publication number
ECSP14013212A
ECSP14013212A ECSP14013212A ECSP14013212A EC SP14013212 A ECSP14013212 A EC SP14013212A EC SP14013212 A ECSP14013212 A EC SP14013212A EC SP14013212 A ECSP14013212 A EC SP14013212A
Authority
EC
Ecuador
Prior art keywords
compounds
btk
quinase
bruton
tyrosine
Prior art date
Application number
Other languages
English (en)
Inventor
Tapia Francisco Javier Lopez
Saul Jaime-Figueroa
Timothy D Owens
Pleiss Christine E Brotherton
Yan Lou
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46690498&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP14013212(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP14013212A publication Critical patent/ECSP14013212A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Esta solicitud describe compuestos que se ajustan a la fórmula genérica I:en la que las variables tienen los significados aquí descritos, y que inhiben la Btk. Los compuestos aquí descritos son útiles para modular la actividad de la Btk y tratar enfermedades asociadas con una actividad excesiva de la Btk. Los compuestos son útiles además para tratar enfermedades inflamatorias y autoinmunes asociadas con la proliferación aberrante de las células B, por ejemplo la artritis reumatoide. Se describen también composiciones que contienen compuestos de la fórmula I y por lo menos un vehículo, diluyente o excipiente.
ECSP14013212 2011-08-17 2014-02-17 Inhibidores de la tirosina-quinasa de bruton ECSP14013212A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161524374P 2011-08-17 2011-08-17
US201261649991P 2012-05-22 2012-05-22

Publications (1)

Publication Number Publication Date
ECSP14013212A true ECSP14013212A (es) 2014-03-31

Family

ID=46690498

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP14013212 ECSP14013212A (es) 2011-08-17 2014-02-17 Inhibidores de la tirosina-quinasa de bruton

Country Status (22)

Country Link
US (1) US8889682B2 (es)
EP (1) EP2744804B1 (es)
JP (1) JP5823616B2 (es)
KR (1) KR20140052032A (es)
CN (1) CN103748088A (es)
AR (1) AR087543A1 (es)
AU (1) AU2012296888A1 (es)
BR (1) BR112014003582A2 (es)
CA (1) CA2841801A1 (es)
CL (1) CL2014000350A1 (es)
CO (1) CO6842020A2 (es)
CR (1) CR20140027A (es)
EA (1) EA024689B1 (es)
EC (1) ECSP14013212A (es)
HK (1) HK1197060A1 (es)
IL (1) IL230561A0 (es)
MA (1) MA35419B1 (es)
MX (1) MX349372B (es)
PE (1) PE20140865A1 (es)
TW (1) TW201311669A (es)
WO (1) WO2013024078A1 (es)
ZA (1) ZA201400739B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2552514T3 (es) 2011-11-03 2015-11-30 Hoffmann-La Roche Ag Compuestos bicíclicos de piperazina
WO2013067264A1 (en) 2011-11-03 2013-05-10 Genentech, Inc. 8-fluorophthalazin-1 (2h) - one compounds as inhibitors of btk activity
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
BR112014010439A2 (pt) 2011-11-03 2017-04-18 F Hoffmann - La Roche Ag compostos, composição farmacêutica, processo de produção, método de tratamento de uma doença ou distúrbio, métodos, kit e uso de uma composição farmacêutica
CN104662018B (zh) 2012-04-20 2017-10-24 阿迪维纳斯治疗有限公司 取代的杂双环化合物、组合物及其医疗应用
WO2013157021A1 (en) 2012-04-20 2013-10-24 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
CN104704129A (zh) 2012-07-24 2015-06-10 药品循环公司 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
WO2014025976A1 (en) 2012-08-10 2014-02-13 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
JP6088063B2 (ja) * 2012-11-16 2017-03-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ブルトン型チロシンキナーゼの阻害剤
MX2015006457A (es) * 2012-11-30 2015-08-14 Hoffmann La Roche Inhibidores de la tirosina cinasa de bruton.
EP2964627B1 (en) 2013-03-05 2017-03-01 F. Hoffmann-La Roche AG Inhibitors of bruton's tyrosine kinase
CN104177338B (zh) * 2013-05-22 2018-04-03 南京勇山生物科技有限公司 一类布鲁顿激酶抑制剂
CA2912359A1 (en) * 2013-07-03 2015-01-08 F. Hoffmann-La Roche Ag Heteroaryl pyridone and aza-pyridone amide compounds
CA2919068C (en) 2013-07-26 2018-03-20 Carna Biosciences, Inc. Triazine derivative
EP3048102A1 (en) * 2013-09-20 2016-07-27 Carna Biosciences Inc. Novel triazine derivative
KR101813830B1 (ko) 2013-12-05 2017-12-29 에프. 호프만-라 로슈 아게 친전자성 작용기를 갖는 헤테로아릴 피리돈 및 아자-피리돈 화합물
EP3042903B1 (en) 2015-01-06 2019-08-14 Impetis Biosciences Ltd. Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
DK3247699T3 (da) 2015-01-22 2019-08-12 Sanofi Aventis Deutschland Proces til produktion of 2-[4-(cyclopropancarbonyl)phenyl]-2-methyl-propannitril
US10208024B2 (en) 2015-10-23 2019-02-19 Array Biopharma Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases
AU2021267373A1 (en) 2020-05-06 2022-12-08 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
WO2023009709A1 (en) * 2021-07-29 2023-02-02 Ajax Therapeutics, Inc. Pyrazolo piperazines as jak2 inhibitors
WO2023086319A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
CN115073299A (zh) * 2022-06-14 2022-09-20 爱斯特（成都）生物制药股份有限公司 一种制备2-氟-3-三氟甲基苯胺的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7683064B2 (en) * 2008-02-05 2010-03-23 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
WO2009098144A1 (en) * 2008-02-05 2009-08-13 F. Hoffmann-La Roche Ag Novel pyridinones and pyridazinones
EP2297142B1 (en) 2008-06-24 2015-10-14 F. Hoffmann-La Roche AG Novel substituted pyridin-2-ones and pyridazin-3-ones
US8299077B2 (en) * 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
AR082590A1 (es) * 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
WO2013067264A1 (en) * 2011-11-03 2013-05-10 Genentech, Inc. 8-fluorophthalazin-1 (2h) - one compounds as inhibitors of btk activity
CA2853138A1 (en) * 2011-12-05 2013-06-13 Immunomedics, Inc. Therapeutic use of anti-cd22 antibodies for inducing trogocytosis

Also Published As

Publication number Publication date
CA2841801A1 (en) 2013-02-21
EP2744804A1 (en) 2014-06-25
CN103748088A (zh) 2014-04-23
CO6842020A2 (es) 2014-01-20
AU2012296888A1 (en) 2014-01-23
JP5823616B2 (ja) 2015-11-25
AR087543A1 (es) 2014-04-03
US8889682B2 (en) 2014-11-18
HK1197060A1 (en) 2015-01-02
ZA201400739B (en) 2016-01-27
IL230561A0 (en) 2014-03-31
EA024689B1 (ru) 2016-10-31
PE20140865A1 (es) 2014-07-19
WO2013024078A1 (en) 2013-02-21
US20130045965A1 (en) 2013-02-21
JP2014521734A (ja) 2014-08-28
CL2014000350A1 (es) 2014-08-22
BR112014003582A2 (pt) 2017-03-14
KR20140052032A (ko) 2014-05-02
MX2014001653A (es) 2014-03-21
EA201490452A1 (ru) 2014-05-30
CR20140027A (es) 2014-03-13
TW201311669A (zh) 2013-03-16
MA35419B1 (fr) 2014-09-01
MX349372B (es) 2017-07-26
EP2744804B1 (en) 2017-05-17

Similar Documents

Publication Publication Date Title
ECSP13013025A (es) Inhibidores de la tirosina-quinasa de bruton
ECSP14013212A (es) Inhibidores de la tirosina-quinasa de bruton
ECSP13012437A (es) Inhibidores de la tirosina-quinasa de bruton
PE20151336A1 (es) Inhibidores de la tirosina-quinasa de bruton
CO6382183A2 (es) Nuevas piridin -2-onas y piridazin -3-onas sustituidas
ECSP10010384A (es) Nuevas piridinonas y piridazinonas
BR112015010693A2 (pt) inibidores de tirosina quinase de bruton
SV2017005561A (es) Metodos para tratar infecciones por el virus filoviridae
UY34201A (es) Compuestos de azaindol y métodos para el tratamiento de vih.
UY34156A (es) Compuestos inhibidores de metaloenzimas
CR20150217A (es) Inhibidores de histona demetilasas
CU20170015A7 (es) Compuesto de (pirazolilamino) pirimidinil biciclo (3.2.1)oct-8-il
BR112015007513A2 (pt) inibidores de tirosina quinase de bruton
BR112014013582A8 (pt) inibidores de quinase de tirosina de bruton
UY34145A (es) Compuestos inhibidores de metaloenzimas
CO6761389A2 (es) Inhibidores de nampt y rock
EA201391626A1 (ru) Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака
BR112015006696A2 (pt) 3-fenilisoxazolina-5-carboxamidas 5-oxi-substituídas e 3-fenilisoxazolina-5-tioamidas 5-oxi-substituídas herbicidas e fungicidas
UY33627A (es) Compuestos para tratar enfermedades neurodegenerativas
ECSP13012985A (es) Pirimidinas sustituidas de diaminocarboxamida y diaminocarbonitrilo, composiciones de las mismas y métodos de tratamiento con las mismas
UY34648A (es) Amidas como inhibidores de pim
CO7111292A2 (es) Derivados cíclicos de diaminopirimidina
GT201400066A (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
DOP2014000074A (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
BR112013002484A2 (pt) composto, composição farmacêutica, métodos para tratar esclerose múltipla e artrite reumatoide, e, uso de um composto.